MNPR insider trading — Monopar Therapeutics
No open-market insider purchases or sales were filed for Monopar Therapeutics (MNPR) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent MNPR insider transactions
Every Form 4 filed by Monopar Therapeutics officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Starr Christopher M | Director | M · Option exercise · 10b5-1 | Direct | 8,400 | $0.01 | $42 | Form 4 |
| Oct 1, 2026 | Starr Christopher M | Director | S · Sale · 10b5-1 | Direct | 8,400 | $78.50 | $659K | Form 4 |
| Sep 30, 2026 | Cittadine Andrew | Chief Operating Officer | M · Option exercise | Direct | 4,384 | — | — | Form 4 |
| Sep 30, 2026 | Cittadine Andrew | Chief Operating Officer | F · Tax withholding | Direct | 1,944 | $79.67 | $155K | Form 4 |
| Sep 30, 2026 | Vu Quan Anh | Chief Financial Officer | M · Option exercise | Direct | 614 | — | — | Form 4 |
| Sep 30, 2026 | Vu Quan Anh | Chief Financial Officer | F · Tax withholding | Direct | 180 | $79.67 | $14K | Form 4 |
| Sep 30, 2026 | Robinson Chandler | Chief Executive Officer | M · Option exercise | Direct | 9,801 | — | — | Form 4 |
| Sep 30, 2026 | Robinson Chandler | Chief Executive Officer | F · Tax withholding | Direct | 4,344 | $79.67 | $346K | Form 4 |
| Sep 24, 2026 | Robinson Chandler | Chief Executive Officer | M · Option exercise · 10b5-1 | Direct | 29,056 | $21.74 | $632K | Form 4 |
| Sep 24, 2026 | Robinson Chandler | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 29,056 | $88.00 | $2.56M | Form 4 |
| Aug 26, 2026 | Rioux Patrice | - | M · Option exercise · 10b5-1 | Direct | 1,380 | $0.01 | $7 | Form 4 |
| Aug 26, 2026 | Rioux Patrice | - | S · Sale · 10b5-1 | Direct | 1 | $111.26 | $111 | Form 4 |
| Aug 26, 2026 | Tsuchimoto Kim R | Director | S · Sale · 10b5-1 | Direct | 4,090 | $111.39 | $456K | Form 4 |
| Aug 25, 2026 | Anderson Raymond | Director | S · Sale · 10b5-1 | Direct | 3,142 | $111.77 | $351K | Form 4 |
MNPR insider trading FAQ
Are insiders buying MNPR stock?
Not on the open market. In the last 90 days, Monopar Therapeutics insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading MNPR?
No insider bought or sold on the open market in the last 90 days.
Where does MNPR insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.